		Accueil	Pour nous joindre

Dernière mise à jour : janvier 2022

Urgence et signalement
1 800 463-9009

Buy Aripiprazole (Abilify) tablets online

How and where to order Abilify (Aripiprazole) pills:

Shop:	PHARMA SHOP - 10% discount coupon hf-5478
Sellers:	ARIPIPRAZOLE STORES
Prices:	from $0.55 per pill
Forms:	5 mg, 10 mg, 15 mg, 20 mg, 30 mg tablets or capsules
Quantity:	30-360 pills
Type:	Abilify (Aripiprazole) brand and generics
Payment:	Visa, Mastercard, AmEx, Cryptocurrencies
Delivery:	Regular and express mail service
Shipping:	Worldwide, including USA, UK, Europe, Canada, Australia

Indications and usage:

Abilify (Aripiprazole) is an atypical antipsychotic. The oral formulations are indicated for:

Schizophrenia.

Acute treatment of manic and mixed episodes associated with bipolar I.

Adjunctive treatment of major depressive disorder.

Irritability associated with autistic disorder.

Treatment of Tourette's disorder.

The injection is indicated for agitation associated with schizophrenia or bipolar mania.

Dosage and administration:

Oral formulations of Aripiprazole (Abilify): administer once daily without regard to meals.

IM injection: wait at least 2 hours between doses. Maximum daily dose 30 mg.

Known CYP2D6 poor metabolizers: half of the usual dose.

Dosage forms and strengths:

Oral formulations of Aripiprazole (Abilify): administer once daily without regard to meals.

IM injection: wait at least 2 hours between doses. Maximum daily dose 30 mg.

Known CYP2D6 poor metabolizers: half of the usual dose.

Contraindications:

Known hypersensitivity to Aripiprazole (Abilify).

Warnings and precautions:

Cerebrovascular adverse reactions in elderly patients with dementia-related psychosis: increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack, including fatalities).

Neuroleptic malignant syndrome: manage with immediate discontinuation and close monitoring.

Tardive dyskinesia: discontinue if clinically appropriate.

Metabolic changes: atypical antipsychotic drugs have been associatedwith metabolic changes that include hyperglycemia/diabetes mellitus, dyslipidemia, and body weight gain.

Hyperglycemia/diabetes mellitus: monitor glucose regularly inpatients with and at risk for diabetes.

Dyslipidemia: undesirable alterations in lipid levels have beenobserved in patients treated with atypical antipsychotics.

Weight gain: weight gain has been observed with atypical antipsychotic use. Monitor weight.

Pathological gambling and other compulsive behaviors: consider dose reduction or discontinuation.

Orthostatic hypotension: monitor heart rate and blood pressure and warnpatients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope.

Leukopenia, neutropenia, and agranulocytosis: have been reported withantipsychotics including Abilify. Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy anddiscontinuation of Aripiprazole should be considered at the first sign of aclinically significant decline in WBC in the absence of other causative factors.

Seizures/convulsions: use cautiously in patients with a history of seizuresor with conditions that lower the seizure threshold.

Potential for cognitive and motor impairment: use caution whenoperating machinery.

Suicide: the possibility of a suicide attempt is inherent in schizophrenia and bipolar disorder. Closely supervise high-risk patients.

Overdosage:

No specific information is available on the treatment of overdose with Abilify (Aripiprazole). An electrocardiogram should be obtained in case of overdosage and if QT interval prolongation is present, cardiac monitoring should be instituted. Otherwise, management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Close medical supervision and monitoring should continue until the patient recovers.

Charcoal: In the event of an overdose of Abilify, an early charcoal administration may be useful in partially preventing the absorption of aripiprazole. Administration of 50 g of activated charcoal, one hour after a single 15mgoral dose of Abilify, decreased the mean AUCand Cmaxof aripiprazole by 50%.

Hemodialysis: Although there is no information on the effect of hemodialysis in treating an overdose with this drug, hemodialysis is unlikely to be useful in overdose management since aripiprazole is highly bound to plasma proteins.

Side effects, adverse reactions:

Commonly observed adverse reactions (incidence >= 5% and at least twice that for placebo) of aripiprazole were:

Adult patients with schizophrenia: akathisia.

Pediatric patients (13 to 17 years) with schizophrenia: extrapyramidal disorder, somnolence, and tremor.

Adult patients (monotherapy) with bipolar mania: akathisia, sedation, restlessness, tremor, and extrapyramidal disorder.

Adult patients (adjunctive therapy with lithium or valproate) with bipolar mania: akathisia, insomnia, and extrapyramidal disorder.

Pediatric patients (10 to 17 years) with bipolar mania: somnolence, extrapyramidal disorder, fatigue, nausea, akathisia, blurred vision, salivary hypersecretion, and dizziness.

Adult patients with major depressive disorder (adjunctive treatment to antidepressant therapy): akathisia, restlessness, insomnia, constipation, fatigue, and blurred vision.

Pediatric patients (6 to 17 years) with autistic disorder: sedation, fatigue,vomiting, somnolence, tremor, pyrexia, drooling, decreased appetite, salivary hypersecretion, extrapyramidal disorder, and lethargy.

Pediatric patients (6 to 18 years) with Tourette's disorder: sedation, somnolence, nausea, headache, nasopharyngitis, fatigue, increased appetite.

Adult patients with agitation associated with schizophrenia or bipolar mania: nausea.

To report suspected side effects of Abilify (Aripiprazole) tablets, contact Otsuka Pharmaceutical, Bristol-Myers Squibb companies or your local FDA.

Drug interactions:

Known CYP2D6 poor metabolizers: administer half of usual dose.

Known CYP2D6 poor metabolizers and strong CYP3A4 inhibitors: administer a quarter of usual dose.

Strong CYP2D6 or CYP3A4 inhibitors: administer half of usual dose.

Strong CYP2D6 and CYP3A4 inhibitors: administer a quarter of usual dose.

Strong CYP3A4 inducers: double usual dose over 1 to 2 weeks.

Use in specific populations:

Pregnancy: aripiprazole may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure.

Lactation: The development and health benefits of breastfeeding should be considered along with the mother's clinical need for Abilify and any potential adverse effects on the breastfed infant from this medication or from the underlying maternal condition.

Pediatric use: safety and effectiveness in pediatric patients with major depressive disorder or agitation associated with schizophrenia or bipolar mania have not been established.

Geriatric use: no dosage adjustment is recommended for elderly patients. Aripiprazole tablets are not approved for the treatment of patients with psychosis associated with Alzheimer's disease.

Hepatic and renal impairment: no dosage adjustment for this medicine is required on the basis of a patient's hepatic function (mild to severe hepatic impairment, Child-Pugh score between 5 and 15), or renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute).

Where to buy aripiprazole online:

To purchase Abilify (Aripiprazole) tablets from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.

Here is a list of popular medications containing aripiprazole as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:

Trade name of the drug	Pharmaceutical forms and doses	Companies
Abilify	Injectable; Injection; 7.5 mg / ml Solution; Oral; 1 mg / ml Tablets, Orally Disintegrating; Oral; 10 mg, 15 mg, 20 mg, 30 mg Tablets; Oral; 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg	Bristol-Myers Squibb Otsuka Pharmaceutical
Abilify Discmelt	Tablets, Orally Disintegrating; Oral; 10 mg, 15 mg	Bristol-Myers Squibb
Arip-MT	Tablets; Oral; 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg	Torrent Pharmaceuticals
Arpizol	Tablets; Oral; 5 mg, 10 mg, 15 mg, 20 mg, 30 mg	Sun Pharmaceutical Industries
Asprito	Tablets; Oral; 10 mg, 15 mg, 20 mg, 30 mg	Intas Pharmaceuticals